,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,3963 Maple Avenue,Suite 350,Dallas,TX,75219,United States,972 499 3350,https://instilbio.com,Biotechnology,Healthcare,"Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.",192,"{'maxAge': 1, 'name': 'Mr. Bronson  Crouch', 'age': 49, 'title': 'Chairman & CEO', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 672367, 'exercisedValue': 0, 'unexercisedValue': 250017}",8,8,9,8,9,1693526400,1672444800,86400,4,0.4701,0.456,0.4273,0.48,0.4701,0.456,0.4273,0.48,0.0,1.273146,-0.7242373,712180,712180,508616,510330,510330,0.44,0.4661,800,1300,55582756,0.41,5.41,0.51896,0.65034,0.0,0.0,USD,-59018200,0.0,68052180,130079000,809620,1233944,1690761600,1693440000,0.0062,0.06842,0.71525,2.38,0.012999999,2.28,0.18741229,1672444800,1703980800,1688083200,-185798000,-1.29,-0.59,0.421,NCM,EQUITY,TIL,TIL,"Instil Bio, Inc.","Instil Bio, Inc.",1616160600,America/New_York,EDT,-14400000,0.4273,5.0,2.0,4.0,5.0,1.7,buy,3,201699008,1.551,-140224000,87098000,10.976,12.003,29.374,-0.18813999,-0.49228,-147474368,-132075000,0.0,0.0,0.0,USD,
1,3963 Maple Avenue,Suite 350,Dallas,TX,75219,United States,972 499 3350,https://instilbio.com,Biotechnology,Healthcare,"Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.",192,"{'maxAge': 1, 'name': 'Dr. Sandeep  Laumas M.D.', 'age': 53, 'title': 'CFO & Chief Bus. Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 489139, 'exercisedValue': 0, 'unexercisedValue': 437900}",8,8,9,8,9,1693526400,1672444800,86400,4,0.4701,0.456,0.4273,0.48,0.4701,0.456,0.4273,0.48,0.0,1.273146,-0.7242373,712180,712180,508616,510330,510330,0.44,0.4661,800,1300,55582756,0.41,5.41,0.51896,0.65034,0.0,0.0,USD,-59018200,0.0,68052180,130079000,809620,1233944,1690761600,1693440000,0.0062,0.06842,0.71525,2.38,0.012999999,2.28,0.18741229,1672444800,1703980800,1688083200,-185798000,-1.29,-0.59,0.421,NCM,EQUITY,TIL,TIL,"Instil Bio, Inc.","Instil Bio, Inc.",1616160600,America/New_York,EDT,-14400000,0.4273,5.0,2.0,4.0,5.0,1.7,buy,3,201699008,1.551,-140224000,87098000,10.976,12.003,29.374,-0.18813999,-0.49228,-147474368,-132075000,0.0,0.0,0.0,USD,
2,3963 Maple Avenue,Suite 350,Dallas,TX,75219,United States,972 499 3350,https://instilbio.com,Biotechnology,Healthcare,"Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.",192,"{'maxAge': 1, 'name': 'Dr. Mark E. Dudley Ph.D.', 'title': 'Chief Scientific Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",8,8,9,8,9,1693526400,1672444800,86400,4,0.4701,0.456,0.4273,0.48,0.4701,0.456,0.4273,0.48,0.0,1.273146,-0.7242373,712180,712180,508616,510330,510330,0.44,0.4661,800,1300,55582756,0.41,5.41,0.51896,0.65034,0.0,0.0,USD,-59018200,0.0,68052180,130079000,809620,1233944,1690761600,1693440000,0.0062,0.06842,0.71525,2.38,0.012999999,2.28,0.18741229,1672444800,1703980800,1688083200,-185798000,-1.29,-0.59,0.421,NCM,EQUITY,TIL,TIL,"Instil Bio, Inc.","Instil Bio, Inc.",1616160600,America/New_York,EDT,-14400000,0.4273,5.0,2.0,4.0,5.0,1.7,buy,3,201699008,1.551,-140224000,87098000,10.976,12.003,29.374,-0.18813999,-0.49228,-147474368,-132075000,0.0,0.0,0.0,USD,
3,3963 Maple Avenue,Suite 350,Dallas,TX,75219,United States,972 499 3350,https://instilbio.com,Biotechnology,Healthcare,"Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.",192,"{'maxAge': 1, 'name': 'Dr. Robert  Hawkins MBBS, Ph.D.', 'title': 'Head of R&D', 'fiscalYear': 2020, 'exercisedValue': 0, 'unexercisedValue': 0}",8,8,9,8,9,1693526400,1672444800,86400,4,0.4701,0.456,0.4273,0.48,0.4701,0.456,0.4273,0.48,0.0,1.273146,-0.7242373,712180,712180,508616,510330,510330,0.44,0.4661,800,1300,55582756,0.41,5.41,0.51896,0.65034,0.0,0.0,USD,-59018200,0.0,68052180,130079000,809620,1233944,1690761600,1693440000,0.0062,0.06842,0.71525,2.38,0.012999999,2.28,0.18741229,1672444800,1703980800,1688083200,-185798000,-1.29,-0.59,0.421,NCM,EQUITY,TIL,TIL,"Instil Bio, Inc.","Instil Bio, Inc.",1616160600,America/New_York,EDT,-14400000,0.4273,5.0,2.0,4.0,5.0,1.7,buy,3,201699008,1.551,-140224000,87098000,10.976,12.003,29.374,-0.18813999,-0.49228,-147474368,-132075000,0.0,0.0,0.0,USD,
